title: Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
abstract: The design of potent and selective non-peptide antagonists of endothelin-1 (ET-1) and its related isopeptides are important tools defining the role of ET in human diseases. In this report we will describe the detailed structure-activity relationship (SAR) studies that led to the discovery of a potent series of butenolide ETA selective antagonists. Starting from a micromolar screening hit, PD012527, use of Topliss decision tree analysis led to the discovery of the nanomolar ET(A) selective antagonist PD155080. Further structural modifications around the butenolide ring led directly to the subnanomolar ETA selective antagonist PD156707, IC50's = 0.3 (ET(A)) and 780 nM (ET(B)). This series of compounds exhibited functional activity exemplified by PD156707. This derivative inhibited the ETA receptor mediated release of arachidonic acid from rabbit renal artery vascular smooth muscle cells with an IC50 = 1.1 nM and also inhibited the ET-1 induced contraction of rabbit femoral artery rings (ETA mediated) with a pA2 = 7.6. PD156707 also displayed in vivo functional activity inhibiting the hemodynamic responses due to exogenous administration of ET-1 in rats in a dose dependent fashion. Evidence for the pH dependence of the open and closed tautomerization forms of PD156707 was demonstrated by an NMR study. X-ray crystallographic analysis of the closed butenolide form of PD156707 shows the benzylic group located on the same side of the butenolide ring as the gamma-hydroxyl and the remaining two phenyl groups on the butenolide ring essentially orthogonal to the butenolide ring. Pharmacokinetic parameters for PD156707 in dogs are also presented.
authors.affiliation: Department of Medicinal Chemistry, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Michigan 48105, USA.
authors.forename: W C
authors.initials: WC
authors.lastname: Patt
authors.forename: J J
authors.initials: JJ
authors.lastname: Edmunds
authors.forename: J T
authors.initials: JT
authors.lastname: Repine
authors.forename: K A
authors.initials: KA
authors.lastname: Berryman
authors.forename: B R
authors.initials: BR
authors.lastname: Reisdorph
authors.forename: C
authors.initials: C
authors.lastname: Lee
authors.forename: M S
authors.initials: MS
authors.lastname: Plummer
authors.forename: A
authors.initials: A
authors.lastname: Shahripour
authors.forename: S J
authors.initials: SJ
authors.lastname: Haleen
authors.forename: J A
authors.initials: JA
authors.lastname: Keiser
authors.forename: M A
authors.initials: MA
authors.lastname: Flynn
authors.forename: K M
authors.initials: KM
authors.lastname: Welch
authors.forename: E E
authors.initials: EE
authors.lastname: Reynolds
authors.forename: R
authors.initials: R
authors.lastname: Rubin
authors.forename: B
authors.initials: B
authors.lastname: Tobias
authors.forename: H
authors.initials: H
authors.lastname: Hallak
authors.forename: A M
authors.initials: AM
authors.lastname: Doherty
mesh_terms: D000284:Administration, Oral; D000818:Animals; D019540:Area Under Curve; D004149:Dioxoles / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D004285:Dogs; D019332:Endothelin-1 / Q000037:antagonists & inhibitors*; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D011817:Rabbits; D051381:Rats; D013329:Structure-Activity Relationship
chemical_list: D004149:Dioxoles; D019332:Endothelin-1; C093322:PD 155080; C093321:PD 156707